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Abstract 
There is a historical interest in improving cognitive performance for individuals in fields 
such as academia. Nootropics, also known as smart drugs, are increasingly being used 
by individuals to obtain desirable cognitive benefits. Research has focused on 
investigating the potential benefits of nootropics through animal studies, however there 
is limited knowledge regarding the potential adverse side effects of these substances in 
humans. An online, active community of nootropic consumers have provided consumer 
experiences and advice for new consumers, to aid in the navigation of the vast nootropic 
online market. The current two-part study aimed to firstly monitor the nootropic market 
available to the Australian consumer, and secondly, to provide a narrative review of the 
top ten most commonly available nootropics. The 12-month monitoring revealed a vast, 
relatively stable nootropic marketplace. Adrafinil, Alpha GPC, Aniracetam, Noopept, 
Oxiracetam, Phenibut, Centrophenoxine, L-theanine, Phenylpiracetam, and 
Paramiracetam were identified as the ten most common nootropics on the market and 
were the focus of the narrative review. The second study revealed several psychological 
(e.g., anxiety and low mood) and other (e.g., physical pain and sleep difficulties) side 
effects of the commonly used nootropics. The current study was limited in that the 
nootropics were not purchased to ensure product availability, and by the validity and 
reliability of consumer reports. It is advisable that clinicians increase their understanding 
of the potential harms nootropics may have on consumers. Future research is required to 
further explore and validate these side effects.   
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The human pursuit of using technology to maximize performance dates back to 
the stone age (Buyx, 2015). In more recent history, humans have developed medical 
technology that not only addresses illness and disease, but also focuses on improving 
what is considered normal human performance (Buyx, 2015; Cavanna, 2015; Kramer, 
1993). Specifically, there has been an interest in improving cognitive performance for 
benefits in fields that rely heavily on cognitive ability (e.g., working memory, attention, 
etc.), such as academia, e-sports (i.e. competitive video gaming) and computer coding 
(Holden, Rodenberg, & Kaburakis, 2017; Talih & Ajaltouni, 2015). Previously, this type 
of technology was labelled as ‘cosmetic psychopharmacology’ (Kramer, 1993). 
However, more recently, a shift in nomenclature has occurred, with terms such as ‘smart 
drugs’ and ‘nootropics’ being more commonplace (Buyx, 2015; Talih & Ajaltouni, 
2015). Buyx (2015) notes that the term ‘smart drug’ is problematic due to the implicit 
message that these substances are smart in their action, or that people who take them are 
inherently smart. These cognitive enhancing drugs have also generated significant media 
attention due to their potential for increased performance, and are known by many 
different names (e.g., nootropics, cognitive enhancers, brain supplements, 
neuroenhancements and smart pills). For the purpose of the current study, the term 
nootropics will be used to describe these cognitive enhancing substances, however it is 
noted that these terms are interchangeable.  
There is a growing body of literature that suggests there has been an increase in 
the use of nootropics (Hupli, Didziokaite, & Ydema, 2016; Mazanov, Dunn, Connor, & 
Fielding, 2013), which has attracted investigation from a diverse range of professionals 
(Dowling et al., 2016). In addition to increases in current empirical literature, media 
coverage has also accumulated. Partridge, Bell, Lucke, Yeates, and Hall’s (2011) 
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examination of media reports, revealed that 66% of the media coverage on nootropic 
drugs referred to academic literature, with a tendency to under-report potential side 
effects. As both the study and public interest for nootropics grows, so do the markets 
that provide these substances to consumers. In 2015, the global market for nootropics 
was valued at $1,346.5 million USD with numbers expected to increase (Acute Market 
Reports, 2016). In line with the growing interest in media coverage and scientific 
literature, the current study aims to contribute to the understanding of nootropics.  
Types and Use of Nootropics  
Nootropic drugs claim to improve specific aspects of cognition such as attention, 
alertness, memory, and cognitive control (Buyx, 2015; Holden et al., 2017; Talih & 
Ajaltouni, 2015). Research on cognitive improvements has predominately focused on 
animal studies, with scarce research involving human samples (Ahmad et al., 2017). 
Notably, there may be a desire for consumers to be on the cutting edge of cognitive 
enhancement, which may in turn result in disregarding the limitations of the methods 
used in supportive research studies. The process whereby researchers do not study a new 
drug in humans until it has undergone safety testing in animal samples, creates an over 
reliance on animal literature for consumers who want to be on the cutting edge. 
Specifically, in Australia, new medications undergo a four-phase clinical trial process 
(see Table 1; Australian Clinical Trails, 2015). The overarching aim of this process is to 
ensure efficacy of the substance to provide expected outcomes, while identifying and 
minimizing risk to human consumers. Nootropic substances are often still in phase zero 
and have not been tested as vigorously.  
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Table 1  
Summary of the Phases of Clinical Trials in Australia (Australian Clinical Trials, 2015) 
Clinical Phase Required Sample Expected Outcome 
Phase Zero Trials 
(exploratory 
studies/pilot studies) 
Testing medication in its infancy 
across animal and very small (n = 1-
2) human samples.  
To identify how the body may 
respond to the experimental 
medication.  
Phase I Clinical Trial Testing new medications/ 
interventions in a small sample of 
human subjects (n = 20-30). 
To identify safe dosage levels 
and potential side effects.  
Phase II Clinical 
Trial 
Testing medications/ interventions 
from Phase I in a larger sample of 
human subjects (n = 100-300). 
Further identify potential side 
effects in a more representative 
sample of consumers.  
Phase III Clinical 
Trial 
Testing medications/ interventions 
for efficacy when compared to 
already ratified medications or 
interventions in a large group of 
humans (approx. n = 300-3000).  
To identify efficacy of 
medication as well as 
continuing to explore side 
effects.  
Phase IV Clinical 
Trial  
Completed when the medication has 
been marketed and is available to the 
consumer outside of clinical trials.   
Monitor efficacy of medication 
in the general population of 
human consumers.  
 
 Another challenge for nootropic research is in regard to the classification of 
nootropic substances. Due to the large number of substances that fall under the umbrella 
term of nootropics, there has been difficulty in the classification and formal 
categorisation of nootropics (Ragan, Bard, & Singh, 2013). Prescription pharmaceuticals 
(e.g., modafinil and methylphenidate) are often prescribed to address a cognitive 
concern due to an underlying illness or psychiatric diagnosis. One example is modafinil, 
a pharmaceutical commonly used in the treatment of narcolepsy and more recently for a 
range of psychiatric, neurological, and medical illnesses (e.g., depression, multiple 
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sclerosis and Lewy bodies dementia; Capouch, Farlow, & Brosch, 2018; Kaufman, 
Menza, & Fitzsimmons, 2002; Myrick, Malcom, Taylor, & LaRowe, 2004; Taylor & 
Russo, 2000; Zifko, Rupp, Schwarz, Zipko, & Maida, 2002). Recently, there has been 
an increase in the use of prescription pharmaceuticals for off-label purposes (Buyx, 
2015). Off-label purposes are described as the use of pharmaceuticals outside of their 
original intention, for example using antidepressants for the treatment of pain 
symptoms. Individuals are using medications such as modafinil for the off-label purpose 
of cognitive benefits (Buyx, 2015; Chatterjee, 2006; Myrick et al., 2004). Synthetic 
compounds have also become more popular and are increasingly being formulated to 
enhance cognition (e.g., Precetatam; Gouliaev, & Senning, 1994). Additionally, other 
commonly known substances such as caffeine and naturally occurring substances such 
as Ginkgo Biloba, Rhodiola Rosea, and Ginseng, are being sought by consumers to 
improve areas of cognition (Suliman et al., 2016; Tabassum, Rasool, Malik, & Ahmad, 
2012). Nootropic blends (i.e. more than one substance combined), both natural and 
synthetic, have also emerged with claims of improved cognition (Cadenhove, Sambeth, 
Sharma, Woo, & Blokland, 2017).  
Upon examining the current literature, nootropics appear to come from a variety 
of sources (e.g., prescription pharmaceuticals, synthetic compounds, and naturally 
occurring substances), largely dependent on their anticipated purpose. Importantly, 
Ragan et al. (2013) indicated that no concrete classification for nootropic substances 
exists. The current study will classify nootropics within three broad categories including 
1) specified (i.e. substances that make up the nootropic are clearly labelled), 2) 
unspecified (i.e. substances are not clearly labelled), and 3) whether the 
specified/unspecified substance is a blend (i.e. more than one substance combined). 
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Table 2 provides examples of nootropics available online, descriptions of the product 
from vendors, and how they would be classified under the current study’s approach.   
Table 2 
Examples of Current Nootropics and Classification  
Nootropic 
Name 
Image Advertised Description Specified/ 
Unspecified 
Blend 
(Yes/No) 
Adrafinil 
 
(Nootropicsdepot, 
September 29, 2017) 
 
 
“Nootropics Depot offers 
5g, 15g or 30g jars of 
Adrafinil powder. 
Nootropics Depot's 
Adrafinil has been lab-
tested and verified for 
both product purity and 
identity.” 
(Nootropicsdepot, 
September 29, 2017) 
 
 
Specified No 
Armodafinil 
 
(ModaPharma, September 
29, 2017) 
“Armodafinil is a more 
recent form of Modafinil, 
consisting only of the 
(−)-(R)-enantiomer. 
Compared to Modafinil, 
Armodafinil has a longer 
duration of action (10 to 
12 hours vs 6 to 8 hours), 
with a more rapid onset 
of action.” 
(ModaPharma, 
September 29, 2017) 
 
 
Specified No 
Citicoline 
 
(Totalnootropics, 
September 29, 2017)  
 
 
 
“Main benefits, supports 
your focus and attention. 
Supports your memory.” 
(Totalnootropics, 
September 29, 2017) 
Specified No 
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Nootropic 
Name 
Image Advertised Description Specified/ 
Unspecified 
Blend 
(Yes/No) 
Ginkgo 
Biloba 
 
 
(Iherb, September 29, 
2017) 
“Our Ginkgo Biloba 
Extract is the finest 
quality available 
worldwide. Scientific 
research has 
demonstrated that 
Ginkgo Biloba Extract 
has powerful free radical 
scavenging activity in 
vitro studies.” 
(Iherb, September 29, 
2017) 
 
 
Specified No 
Modafinil 
 
(ModaPharma, September 
29, 2017) 
“Modafinil is a eugeroic 
drug or wakefulness-
promoting agent. 
Prescribed around the 
world for chronic fatigue 
syndrome, obstructive, 
sleep apnea, shift-work, 
sleep disorder, ADHD 
and Narcolepsy.” 
(ModaPharma, 
September 29, 2017) 
Specified No 
Noocube 
 
(Noocube, September 29, 
2017) 
“NooCube is a 
synergistic blend of 
nootropics which helps 
support and enhance 
your focus, mental speed 
and memory. Safely and 
effectively improve your 
cognitive functioning 
with this powerful blend 
of vitamins, amino acids 
and other essential 
building blocks for a 
healthy, well-functioning 
brain.” 
(Noocube, September 29, 
2017) 
 
 
 
Umspecified Yes 
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Nootropic 
Name 
Image Advertised Description Specified/ 
Unspecified 
Blend 
(Yes/No) 
Nootroo  
 
(Nootroo, September 29, 
2017) 
“Nootroo's tagline is The 
Gold Standard in 
Nootropic, because of 
our dedication to 
creating the best 
nootropics possible, by 
using only the purest, 
most-effective ingredients 
and never cutting any 
corners.” (Nootroo, 
September 29, 2017) 
 
Unspecified Yes 
Piracetam 
 
(Nootropicsdepot, 
September 29, 2017) 
“Piracetam is a 
nootropic compound in 
the ‘racetam’ family that 
is structurally similar to 
the neurotransmitter 
GABA (though it does 
not function in the same 
way). As the ‘parent 
molecule’ of the racetam 
family, Piracetam was 
first synthesized in 1964. 
All other racetams, 
including others like 
Aniracetam, share the 
same 2-pyrrolidone base 
structure” 
(Nootropicsdepot, 
September 29, 2017) 
 
Specified No 
Rhodiola  
 
(Iherb, September 29, 
2017) 
“generally known as an 
‘adaptogen’, a term 
which refers to any agent 
possessing the ability to 
support the body's 
natural capacity to adapt 
to life's changing 
conditions.” 
(Iherb, September 29, 
2017) 
 
 
Specified No 
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Despite the value of nootropics on the market, evidence of their effectiveness for 
improving human cognition is scarce, and information regarding their potential for 
adverse side effects is limited. Additionally, the research that does exist is criticised 
based on factors such as small sample sizes and poor representativeness of samples 
(Ahmad et al., 2017; Buyx, 2015; Cadenhove, 2017; Carton et al., 2018; Smith, & 
Farah, 2011). Foreseeably, there is a risk to consumers, as the size of the nootropics 
market is large and there is a lack of reliable information regarding these substances, 
making it difficult to be an informed consumer. Despite the growing nootropics 
marketplace, there is a gap in the literature in regard to the various types of nootropics 
that are available and being readily purchased by consumers. The current study aims to 
address this gap by monitoring the online nootropic marketplace, based on previously 
used substance monitoring systems (Bruno, Poesiat, & Matthews, 2013; Psychonaut 
Web Mapping Research Group, 2010).  
Prevalence of Nootropic Use 
Existing literature has indicated academics, students, scientists, pilots, and 
gamers, are populations likely to use nootropics to enhance performance in their 
respective fields (Buyx, 2015; Ragan et al., 2013; Savulich et al., 2017; Van Zyl et al., 
2017). The media however, has been noted to exaggerate the use of nootropics, often 
reporting their use as ‘common place’ amongst students (Buyx, 2015; Ragan et al., 
2013). Ragan et al. (2013) reviewed nootropic prevalence literature, reporting nootropic 
use rates between 1% - 33% internationally. The samples differed substantially in regard 
to country (e.g., Germany, United Kingdom, Demark, Belgium and Iran), population 
(e.g., medical students, staff and employees), and nootropic studied (e.g., modafinil, 
unspecified stimulants, caffeine and methylphenidate), emphasising the difficulty in 
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obtaining reliable and meaningful prevalence data. A review of the misuse of 
medication studies by Wilens et al. (2008) identified that five to nine per cent of US 
school age students, and five to 35% of US university students, reported using non-
prescribed cognitive enhancement medication originally prescribed for individuals with 
Attention-Deficit Hyperactivity Disorder (ADHD) in the prior year.  
Ragan et al. (2013) suggests a lack of concrete prevalence data exists due to 
inconsistency regarding methodologies and samples. Furthermore, little is known about 
the prevalence of nootropic use outside of student populations in the US (Smith & 
Farah, 2011). There is a trend that individuals are using nootropics at an increasing rate, 
supporting the media’s portrayal emphasising more prevalent use of nootropics in 
populations that are being most heavily researched (i.e. student populations).  
Nootropic Use in Australia  
Limited studies have examined the prevalence of nootropic use in Australia. 
Riddell, Jensen, and Carter (2017) reported that in a national sample of 633 Australian 
university students, 51% had used illegal and legal nootropics, at least once in their 
lifetime, with the intention of achieving cognitive benefits. Furthermore, findings 
suggested relatively low use of illicit drugs compared to the use of prescription 
nootropics, with modafinil being the most commonly used nootropic (Riddell et al., 
2017). Furthermore, only an estimated 6.3% of students reported using a prescription 
nootropic substance (e.g., beta-blocker, dexamphetamine, modafinil) at least once, with 
modafinil being the substance most frequently used (Riddell, 2017). The use of non-
prescription substances (e.g., caffeine pills, energy drinks and coffee) for cognitive 
enhancements was more common, with 50.6% of students using these at least once 
(Riddell, 2017). Illicit substances were less commonly used for cognitive enhancement, 
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with approximately two per cent of students using these substances (Riddell, 2017). 
Conversely, the study indicated university students more commonly used legal 
enhancers (e.g., caffeine pills and energy drinks), in an attempt to experience cognitive 
benefits. In a 2015 Australian cross-sectional sample (n = 763) that monitored the use of 
psychostimulant and related drug use (Nelson & Lenton, 2017), 18.2% of frequent 
psychostimulant users (e.g., ecstasy and related drugs) had used nootropics in the 
previous six months. Dexamphetamine, methylphenidate, modafinil, and racetams (e.g. 
Aniracetam, Oxiracetam, Phenylpiracetam, and Pramiracetam) were the most commonly 
reported nootropic substances used (Nelson & Lenton, 2017). Nelson and Lenton (2017) 
noted that being a university student was a predictor for both over-the-counter nootropic 
and illicit nootropic use in this sample.  
Similar to international consumers, Australian consumers have reported using 
nootropics to improve various areas of cognition, specifically concentration, academic 
performance, motivation for study, and increased rate of task completion (Nelson & 
Lenton, 2017). Jensen, Forlini, Partridge, and Hall (2016) noted that Australian students 
are more likely to use nootropics near task deadlines, where students were unable to use 
non-substance related coping strategies (i.e. emotional coping) to manage their 
workloads.  
A substantial proportion of illicit drug consumers who also use nootropics, 
source their nootropics from online vendors, particularly those who reported consuming 
racetams (Nelson & Lenton, 2017). In a recent media article, McNeilage (2018) noted 
that ten Australian high school students were admitted to hospital due to intoxication 
(i.e. dizziness and nausea) after consuming Phenibut, a nootropic purchased online. 
These current insights into nootropic use in Australian consumers, highlight the 
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importance of expanding the literature to provide up to date information regarding the 
potential side effects of nootropic use.  
Reddit and Nootropics  
One of the factors that may have contributed to the expansion of nootropics use 
is the online community. Reddit is the largest online forum, described as ‘the front page 
of the Internet’ (Squier & Fisk, 2013), and has a sub-forum dedicated to nootropics 
(‘r/nootropics’). Squier and Fisk (2013) provided a commentary on the importance of 
the Reddit community in allowing new consumers to access r/nootropics to obtain 
information regarding the common uses, distribution, and education of nootropics. The 
r/nootropics community was described as medium sized (approximately 25,000 
subscribers) in 2013 (Squier & Fisk, 2013). In 2018, this number increased to 143,000 
subscribers (Reddit, June 2018).  
Often subscribers post their first-hand experiences with nootropics, ask 
questions, post research articles, review sellers of nootropics (‘vendors’), and engage in 
other nootropic-based discussion. Squier and Fisk (2013) suggest that the Reddit 
community have allowed for first time users of nootropics to have an accessible source 
of information from past users. It is noted by Squier and Fisk (2013) that the 
r/nootropics community have become critical of the empirical literature, as the literature 
has not caught up with consumer reports of cognitive benefits. This is foreseeably 
dangerous, as if consumers are focused upon subjective reports of cognitive benefits 
rather than potential side effects, there is an unknown possibility for adverse outcomes. 
Specifically, the enthusiastic but anecdotal nature of these reports, combined with the 
absence of a clear guide to benefits and risks, increases the risk to consumers. 
Furthermore, there is a need for future research to explore these gaps in the literature to 
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inform consumers, to reduce the misuse of nootropics given the effects are currently 
unclear.  
To the author’s knowledge, the literature has not yet examined public forum user 
reports for potential side effects of widely available nootropics. This is a method that 
has been adopted previously in consumers of novel illicit substances (e.g., Poesiat & 
Bruno, 2013). Therefore, as there is a large public forum in which nootropic consumers 
post their experience, these forums may be useful in gathering and reviewing the 
experienced side effects of these substances.  
Current Challenges and Concerns Regarding Nootropics 
With the use of nootropic drugs becoming more widespread, ethical issues have 
arisen. Cakic (2009) noted the similarity of nootropic drug use in academia to 
performance enhancing drugs in competitive sport. There are concerns that the use of 
nootropics will become generalised and this will place non-users at a disadvantage 
(Cakic, 2009). This trend may in turn force non-users to use nootropics to keep up with 
students using nootropics. E-sports (i.e. competitive video gaming) has faced similar 
challenges with athletes (i.e. professional gamers) using nootropics (e.g., modafinil, 
methylphenidate, and dextroamphetamine) to gain a competitive gaming advantage 
(Holden, Kaburakis, & Tweedie, 2018). In an attempt to restrict the effect of nootropics 
in e-sports, policy has been discussed and implemented to ensure competitions are fair 
and not subjected to doping (Holden et al., 2017; Holden et al., 2018). As individuals are 
using medications that have not been prescribed to them (e.g., dexamphetamine) or 
substances in which there has been no human safety checking, concerns have 
accordingly been raised. These concerns include the potential risks of adverse events as 
a result of the consumption of these substances given the lack of medical monitoring, or 
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oversight by the consumer. Further research and education for potential consumers has 
been highlighted as a key clinical consideration to be addressed (Wilens et al., 2008). In 
addition to concerns regarding the medical implications for the consumption of 
unprescribed medications, concerns associated with the possible mental health effects of 
nootropic drugs have also been identified. With the rise of nootropic use, there are 
concerns around how to regulate, provide relevant information (e.g., dosage, evidence-
based risks, and benefits), and manage the legal supply of nootropics (Cakic, 2006; 
Farah et al., 2004; Ragan et al., 2013).  
Mental Health and Nootropics 
Talih and Ajaltouni (2015) aimed to raise awareness to physicians, 
psychologists, psychiatrists, and other health professionals, on the potential negative 
effects of nootropic drugs. Their study revealed commonly used nootropics (e.g., 
Armodafilil, Citicoline, Piracetam, Amapakines), their side effects (e.g., headaches, 
tremors, diarrhoea, etc.), and their desired psychotropic effect (e.g., wakefulness, 
memory, cognition, etc.). They also presented four case studies of young, American 
adults who had used such nootropics. The first case study described a 19-year-old male 
that had been treating his ADHD and depression with Citicoline, a nootropic he had 
purchased online. The use of this drug resulted in the individual being admitted to a 
psychiatric hospital with psychosis and paranoia with self-harming behaviours. The 
second case study described a 24-year-old male presenting with agitation, anxiety, and 
hypersomnia, related to Cerebrolysin use, a nootropic drug he had purchased to enhance 
cognitive performance. The third case study described a 28-year-old female who 
presented to the emergency room with insomnia, anxiety, and panic attacks. This 
individual admitted to using Armodafinil, a nootropic drug she had purchased online to 
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help with the academic stresses of university. The final case study noted a 17-year-old 
male who was admitted to hospital due to elevated levels of restlessness and paranoia. 
The patient disclosed the use of Piracetam, a nootropic purchased online, which the 
consumer believed was safe to use as it was advertised as a “natural remedy”. In a 
further case study of nootropic use, Wong, Little, Caldicott, Easton, and Greene (2015) 
described a 43-year-old male who had consumed Phenibut, a nootropic that has become 
widely available online, to self-treat insomnia. The male presented to the emergency 
room with increased agitation and involuntary muscle contractions. Due to the severity 
of his symptoms he had to be stabilised in the intensive care unit. Historical information 
identified that the individual had previously been admitted to the hospital following 
Phenibut use on three separate occasions. Wong et al. (2015) noted increasing concerns 
around nootropic drugs being available online and their unknown physical and mental 
health side effects. These case studies suggest that there are potential mental health risks 
for nootropic use (Talih & Ajaltouni, 2015; Wong et al., 2015). Talih and Ajaltouni 
(2015) suggested that it is particularly important for mental healthcare professionals to 
be aware of nootropic drugs and their potential dangers. This is important so that 
healthcare professionals can consider the side effects during assessment, and to 
understand their potential dangers and how this may impact treatment progression for a 
client using nootropics.  
The research currently available suggests nootropic consumers have experienced 
negative side effects as a result of their nootropic use (Nelson & Lenton, 2017; Ragan et 
al., 2012; Talih & Ajaltouni, 2015). However, there appears to be a lack of large-scale 
studies investigating such effects, and current research has largely relied on case studies 
(Talih & Ajaltouni, 2015; Wong et al., 2015). Future research specifically focusing on 
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which substances are available and what side effects are associated with that type of 
nootropic, is required to reduce the harms associated with nootropic use. The current 
study therefore aims to provide a commentary of consumer experiences of nootropic 
use, with a focus on the mental health side effects for these consumers.  
Current Study Aims 
It appears that the nootropic market is accessible to consumers, but specific 
details such as nootropic type and availability are not yet clarified. Some of these 
substances being legal (e.g., Ginkgo Biloba and Piracetam) and some being illegal (e.g., 
modafinil and adrafinil; Australian Government Department of Health, 2017) to buy, 
further emphasises the need for an understanding of the nootropic drugs available to 
Australian consumers. More importantly, as both legal and illegal substances are 
available through the Internet but have not yet had safety testing (and are typically sold 
as being ‘not for human consumption’), these substances may have unforeseen effects 
which need to be identified and further explored.  
The current study aims to assess the existing nootropic market with an emphasis 
on substances available to Australians, through a 12-month pilot web monitoring system 
based on the methodologies of a previous Emerging Psychoactive Substances (EPS) 
monitoring framework (Bruno et al., 2013; Psychonaut Web Mapping Research Group, 
2010). The 12-month monitoring will identify nootropics readily available to the 
Australian consumer. In addition to monitoring the nootropics and their respective 
online vendors, the current study also aims to provide a brief review of the 10 most 
commonly available nootropics from this monitoring period. Furthermore, qualitative 
information from popular online forums will be used to provide commentary on the 
potential side effects of nootropic use, with a focus on mental health effects of both one-
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off and regular nootropic consumers. Overall, the study aims to provide a systematic 
approach to understanding nootropic substances and clinically relevant side effects. 
Study 1  
Method 
Design  
Study 1 utilised an Internet monitoring methodology previously used to monitor 
emerging psychoactive substance trends in Europe and Australia (Psychonaut Web 
Mapping Project, 2010; Bruno et al., 2013) to monitor nootropic substances. The 
monitoring system aimed to identify the number of vendors selling nootropic drugs, 
survival rates of these online vendors, and the types of nootropics available, within an 
Australian context. Monitoring was conducted on the surface web using popular search 
tools including Google, Yahoo, and Bing, as the aim was to mimic the search and access 
process that may be used by an individual consumer seeking to purchase these 
substances.   
Procedure  
Initial search process: Target identification. To identify frequently used 
Internet search terms for nootropics, common nootropic Internet forums were examined 
(e.g., www.reddit.com/r/nootropics; see Appendix A). Once common terms were 
identified (e.g., ‘smart drugs’; see Appendix B), they were analysed using Google 
Trends. Google Trends identifies how popular a search term has been for each country 
in the world on a relative scale of 1-100 during the last 12 months. The current study 
included Australian search terms that were identified to have a score of 30 or above. 
These included ‘smart drugs’, ‘nootropics Australia’, ‘modafinil’, ‘nootropic’, ‘noot’, 
‘cognitive drugs’, ‘racetams’ and ‘cognitive enhancers’.  
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First month search process. The monitoring began in July 2017 and for the first 
month of monitoring, the eight identified search terms (i.e. smart drugs, nootropics 
Australia, modafinil, nootropic, noot, cognitive drugs, racetams and cognitive 
enhancers) were used. These terms were entered into the top three Australian search 
engines (i.e. google.com.au, yahoo.com, and bing.com; Statcounter Global Stats, 2016). 
Default search settings were used with no additional add-ons that could potentially block 
sites (e.g., ad blocker). The aim of this process was to replicate the experience of a 
consumer should they be conducting an Internet search for these products. Each search 
term was entered individually into each search engine to uncover nootropic vendors (i.e. 
websites that directly offered nootropics for sale). These searches for each term, on each 
search engine, were terminated after 100 search results discovered no new vendors.  
When a vendor was identified to be selling nootropic drugs, it was checked to 
see if it would ship to Australian customers, by undergoing the procedure to purchase 
nootropics for sale and inputting an Australian shipping address. Only vendors that 
would ship to Australia were included in the monitoring. A listing of each vendor, and 
of the nootropic products that were available for sale to Australian based customers was 
made. 
Second and subsequent month search process. Monitoring was conducted 
once a month, for 12 months, on the last seven days of each month. At each new 
monthly search phase, previously identified vendors were assessed directly to determine 
if they were still accessible. For each vendor, the products that they had available for 
sale to Australians were recorded. Each month, the initial list of search terms (i.e. smart 
drugs, nootropics Australia, modafinil, nootropic, noot, alpha brain, cognitive enhancer, 
and racetams) was entered into Google, Bing, and Yahoo search engines to identify 
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nootropic retailers. In addition, the names of the ten most commonly identified products 
identified for sale at vendors (e.g., Adrafinil) were added into the search list. In the first 
month these included Adrafinil, Noopeept, Phenibut, Aniracetam, Alpha GPC, 
Oxiracetam, L-theanine, Phenylpiracetam, Centrophoxine, and Pramiracetam. This list 
was cumulative with more terms being added each month. The drug name would remain 
in the search even if they were no longer in the top ten for that month. This process had 
been previously adopted in monitoring of novel psychoactive substances (Bruno et al., 
2013; Van Buskirk, Roxburgh, Bruno, & Burns, 2013). 
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Results 
 
The 12-month Internet monitoring revealed 52 unique web vendors selling 
nootropic substances available for purchase by Australian consumers. Of the vendors 
discovered, a total of nine vendors either closed, stopped taking new subscribers, or 
were inactive over the period of monitoring. An average of 0.8 (range 0-4) sites were 
gained per month, with an average of 1.6 (range 0-5) lost each month (see Figure 1). 
Vendors remained stable, with all vendors lasting at least seven months of monitoring. 
Interestingly, over the final six months, only 82.7% of vendors remained, with an 
average drop of 1.4% per month (range 0-5%; see Figure 2). Additionally, monitoring 
revealed a total of 342 nootropic substances available to the Australian consumer. Of the 
identified nootropics, 79.8% were specified compounds, with 48.7% of these specified 
compounds sold in blends (i.e. containing multiple substances). The remaining 20.2% 
were unspecified compounds, with 79.7% of these being sold in blends. An average of 
8.3 (range 0-42) substances were added each month, with an average of 5.9 (range 0-17) 
lost each month (see Figure 3). After six months of monitoring, 96.0% of nootropic 
substances remained, with an average drop of 0.8% per month (range 0-2%; see Figure 
4.)  
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Figure 1. Vendors selling nootropics to Australians over the 12-month period. Light 
grey areas are new vendors identified each month, with the line indicating number of 
sites lost each month. 
 
 
Figure 2. Percentage of vendors remaining during the final six-months of monitoring. 
Note: this includes only vendors first identified in the first 7 months of assessment 
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Figure 3. Nootropic substances available to Australians over the 12-month period. Light 
grey areas are new substances identified each month, with the line indicating number of 
substances lost each month.  
 
  
Figure 4. Percentage of substances remaining after a six-month period of monitoring. 
Note: this includes only vendors first identified in the first 7 months of assessment 
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GPC, Aniracetam, Centrophenoxine, L-theanine, Noopept, Oxiracetam, Phenibut, 
Phenylpiracetam, and Pramiracetam.  
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Box 1: All nootropics identified for sale to Australia as single products where content 
was specified to the consumer 
5-HTP 
ACAI 
Acetyl-L-Carnitine 
Adaptongen 
Adrafinil 
Agmatine Sulfate 
ALCAR 
Alpha GPC  
Aniracetam 
Ashwagandha 
Bacopa Monniera 
Baicalin 
Barley Grass 
BCAA 
Berberine 
BETA Alanine 
Black Hoof 
Mushroom 
Bromantane 
Calcium D-Glucarate 
CDP Choline 
Centrophenoxine 
Chaga Mushroom 
Extract  
Choline Bitartrate 
Cissus 
Quadrangularis 
Citicoline 
Cocoa Extract 
Coenzye Q10 
Coluracetam 
Conjugated Linoleic 
Acid 
Controlled Labs 
Gamer up 
Cordyceps 
Creatine 
CRL 40,940 
Curcumin 
CX516 
Cyclazodone 
Cyracos Lemon 
Balm 
Cytisine 
DHA 
DHM 
Dihydroxyflavone 
Dl-Phenylalanine 
DM235 
DMAE 
DMHA 
Dopamine 
Emoxypine 
EVP-6124 
Exoxypine 
Fasoracetam 
Fenozolone 
Forskolin  
GABA 
Galantamine 
Gastrodin 
Ginkgo Biloba 
Ginseng 
Goji Berries 
GS15-4 
Gynostemma 
Hordenine 
Huperzia Serrata 
Huperzine A 
Hydrafinil 
Hydroxytyrosol 
Hyperzine 
Idebenone 
IDRA-21 
Inositol 
Iodine 
KSM-66 
L-Arginine 
L-Carnosine 
L-dopa 
Lecithin 
Lion's Mane 
L-Phenylalanine 
L-theanine 
L-tyrosine 
MACA 
Magnolia Bark Extract 
Maitake 
Melatonin 
Memantine 
Methyl Folate 
Milk Thistle  
Mitogen 
Modafinil 
Modalert 
Modvigil 
N-acetyl L-cystenine 
N-acetyl L-tyrosine 
N-acetylcysteine 
NeuroMaster 
Noopept 
Octane 
Omega-3 fish oil 
Opti-Dhea 
Oxiracetam 
Palmitoylethanolamide 
Phenibut 
Phenylpiracetam 
Phosphatidylserine 
Picamilon 
Piracetam 
Policosanol 
Polygala Tenuifolia 
Poria 
Pramiracetam 
PRL-8-53 
Pterostilbene 
Purified Shilajit 
Pyrroloquinoline 
Red Relshi Mushroom 
Reishi Mushroom 
Resveratrol 
Rhodiola Rosea 3 
Royal Jelly 
S17092 
Sacred Lotus 
SAMe 
Serotonin 
Sulbutiamine 
Sunifiram 
TeaCrine 
Theacrine 
Tianeptine 
Tongkat 
Toremifene Citrate 
Tribulus 
Trubrain 
Unifiram 
Uridine 
Uridine Monophosphate 
Valerian root 
Vincamine 
Vinpocetine 
White Jelly Mushroom  
Zembrin 
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Box 2: All nootropics identified for sale to Australia as multiple products combined as a 
bland where content was specified to the consumer 
1-2 Go 
7-keto DHEA 
AAKG 2:1 
Acetyl-L-Tyrosine 
ActiGrape 
ADK 
Alaskrill Fish 
Alpha Brain 
Amino Focus 
ANS Performance 
Antarctic krill oil 
Arginine 
Alphaketogluterate 
Ashwatrax 
BaCognize 
Biocreatine 
Brain Antioxidai 
Brain Elevate 
Brain Smart Focus 
Brain Smart Memory 
Brain Smart Mood 
Brain smart Ultra 
BSN Neuro Fx  
Bullet proof Ageing 
formula 
Burner Combination 
Caffeine/Nalt 
Caffeine+ L-
Theanine 
Camellia Sinensis 
Chocamine Plus 
Choline & Inositol 
Ciltep 
CinnaTrax 
Cleanse Liver 
Support 
CoQsol-CF 
Cratine Monohydrate 
Creatine Ethyl Ester 
Creatine Nitrate 
Crossbiotics 
D Aspartic Acid 
D-Cycloserine 
Diindolylmethane 
DMAE L-Bitartrate 
DopaTrax 
D-Ribose 
DTOX 
EGCG 
Evergreen Brain Function 
Eye Armor 
Ez Mega 3 
FenuTrax 
Flavonoids 
Flow 
Forbose 
Fortilyte 
Ginkgo Viloba 
Glutathione 
Grape seed extract 
Green Tea Extract 
HMB 
Joints Capsules 
KADO-3 
KetoPrime 
KetoShield 
Konjac Root 
Laxogenin 
l-citrulline Dl-Malate 
Lemon Balm 
Liposomal Phenibut 
Lithium 
Lithium Orotate 
Longvida 
L-Phenylalanince 
L-proline 
Lutein& Zeaxanthin 
Magnesium Aspartate 
Magnesium L-Threonate 
Magnesius L-threonate 
Methyl B-12 
Methylcobalamin 
Methylene Blue 
Mucuna 
Mycomind 
Myo-Inositol 
N-Acetyl Semac Amidate 
NADH 
NA-R-ALA Stabilized R-
Lipoic 
Neuro Fx 
Neuro Vita 
Neurochill 
Neuroprime 
Nexus 
Niacinamide 
Noocube 
Optimal Sleep 
OptiVasc 
Panax Ginseng 
Pantethine 
PEA-P HCI 
Perluxan 
Phenibut FFA 
Phenibut/Insositol 
Polyphenomenal 
PPAP HCI 
PQQ 
Probiotic complex 
Proviotic 
Pump Fx  
Pyridoxine HCL 
R Alpha Lipoic 
Racetam 
R-ALA Cyclodextrin 
Raloxifene 
R-alpha-Lipoic-acid 
Rasberry Ketone 
RGPU-95  
Rhodiola crenulata 
Schizandrol A 
Semax 
SR-9009 
Sucralose 
Sunhorse Energy NanoMojo 
Liposomal Adaptogenic 
Super B12 
Super Rhodiola 
Taurine 
TestoTrax 
Thozalinone 
Turkey Tail 
Ultra Caffeine 
Unfair Advantage 
VibraJoint 
Vinpocetine 
Vitalify 
Wellness Formula 
Zinc with copper 
ZMA 
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Box 3: All nootropics identified for sale to Australia as single or multiple products 
combined  
as a bland where content was not specified to the consumer 
Adaptrax 
Ageless 
AMP'D 
Artvigil 
BCAA 2-1-1 
Brain Minits 
Brain speed 
Brain stack 
Cortex 
DMAA 
DNA Pharma 
Doze 
Electrolyte 
Epicor 
Fladrafinil 
focus up  
Focus3d 
GTS-21 HCI 
HemoLift 
Immuni Prime 
IQUZIL 
Kimera 
Kudingcha Tea 
Limitless NZT-
48+Restoramones  
Magtech 
Memory Complex 
Mind Lab Pro 
MODafinil 
Modafy 
Mood and Memory 
Mycoboost 
N03X 
Nefiracetam 
Neourodrive 
Nootroo 
Nootropics Brain support 
Nootropix 
Noowave POWR 
NooWave SWELL 
NSI-189 
NutraDIM 
NutraRez 
Pamella 
Peak Chocolate 
Pomella 
Pregnenolone 
Prevagen 
Pre-Workout Nootropic 
Pyritinol HCL  
Rave 
Rise 
Senegenin 
Sensoril 
Sleep Mode 
Sprint 
Study Juice 
switch 
Synapsa 
Thermal Switch 
Think-Rite 
Total Focus 
Tranquilora 
Triacetyluridine 
True Calm 
Ultracholine 
Unwind 
Waklert 
Yawn 
Zen mode 
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Preliminary Discussion 
The current study assessed the existing nootropic market available to Australian 
consumers over a 12-month period, using similar methodologies to other monitoring 
studies of substances operating in legally grey areas such as novel psychoactive 
substances (Bruno et al., 2013). The monitoring revealed a substantial number of 
vendors that Australian consumers could access and order nootropic substances from. 
These vendors had a large variety of nootropics available, all advertising cognitive 
enhancements. In line with previous research, the monitoring revealed several different 
types of nootropics were available, such as prescription pharmaceuticals (e.g., 
modafinil), synthetic compounds (e.g., Oxiracetam, Noopept, and Adrafinil), and 
naturally occurring substances (e.g., Bacopa Monnieri, Ginkgo Biloba, and Lion's 
Mane). Substances were commonly sold in the form of tablets, powders, and liquids, as 
both specified and unspecified compounds and blends. The nootropic market was stable 
across the 12 months of monitoring and the current study has provided an accurate 
picture of the existing nootropics available to the Australian consumer. 
Interestingly, stores would often advertise cognitive benefits of the nootropics in 
a variety of ways. Some vendors would use professional reviews (purported to be) from 
individuals working in fields related to cognitive ability (e.g., psychologists, 
neurologists, and doctors: see Table 3). These forms of advertising appeared to use the 
credibility of professionals to instil trust in the nootropic products, similar to 
medications advertised online (Hoffman & Wilkes, 1999). Other vendors provided links 
to research for each available nootropic, which highlighted that particular nootropics 
researched benefits. Consistent with the current literature, these were often animal 
studies (Ahmad et al., 2017). Additionally, these studies were often difficult to interpret 
due to their complex scientific language. Most vendors provided consumer reviews of 
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specific products or links to forums such as r/Nootopics. The majority of vendors did 
not provide any information on adverse side effects associated with mental health. 
Specifically, vendors would often list positive benefits in the nootropic product 
description with limited to no information of perceived side effects (see Figure 5). It is 
conceivable that it would be difficult for consumers to filter through the provided 
information to identify and be fully informed regarding the potential cognitive benefits, 
research identifying benefits, and potential side effects associated with each nootropic 
available. Additionally, consumers may be susceptible to confirmation bias focusing on 
information presenting potential benefits, rather than negative side effects. These factors 
make it difficult for consumers to be informed when purchasing nootropics online. The 
Therapeutic Goods and Administration Board requires a comprehensive description of 
pharmaceuticals (see Figure 6) to ensure transparency for consumers, something 
currently absent from nootropic vendors. With the information presented to consumers 
not detailing sufficient information to inform the consumer, individuals will have 
difficulty identifying information that is important to prevent risk (e.g., recommended 
dosage, what side effects are possible and when to become concerned when using the 
nootropic they have purchased online).  
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Table 3 
Examples of Endorsement of Nootropic Vendors 
Nootropic Name Examples 
MindLabPro 
 
Noocube 
 
Axonlabs 
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Figure 5. Example of product description provided (Nootropicsdepot, October 3, 2018). 
Note that the parent drug, modafinil, is prescribed in doses of 200mg, and the more 
active adrafinil is sold in quantities of 5-30g. 
 
Figure 6.Consumer medicines information guidelines (Australian Government 
Department of Health, October 3, 2018)  
 In line with previous Australian research, racetam (e.g., Piracetam and 
Aniracetam) based nootropics were readily available to the consumer across most 
vendors, with Aniracetam, Oxiracetam, Phenylpiracetam, and Pramiracetam being in the 
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top ten most commonly available nootropics presented in Table 4 (Nelson & Lenton, 
2017). Conversely, forms of modafinil (e.g., Provigil, Modvigil, Modalert, and Alertec) 
were not frequently discovered during the monitoring, despite previous research 
suggesting modafinil is a popular nootropic (Nelson & Lenton, 2017). This may be 
further explained by modafinil being a Schedule 4 (i.e. a medication that requires a 
prescription from a doctor) substance in Australia (Australian Government Department 
of Health, 2017), and is therefore less likely to be sold illegally from an online vendor. 
Further information supporting this trend, comes from previous research establishing 
that Australian consumers purchased their modafinil from a dealer or friend (Nelson & 
Lenton, 2017).  
Table 4 
Twenty Common Nootropics identified from Vendors Each Month  
Month 1 2 3 4 5 6 7 8 9 10 11 12 
Adrafinil 11 17 17 17 17 17 17 14 14 13 13 13 
Alpha GPC 10 15 18 18 18 18 18 15 15 13 13 14 
Aniracetam 10 12 14 14 14 14 14 11 11 10 10 12 
Noopept 10 13 15 15 16 16 16 13 13 12 11 12 
Oxiracetam 10 13 15 15 15 15 16 13 13 12 12 13 
Phenibut 10 12 13 13 13 13 13 10 10 10 10 12 
Centrophenoxine 8 11 11 11 11 11 11 10 10 10 10 10 
L-theanine 8 12 17 20 17 17 17 15 15 14 14 16 
Phenylpiracetam 8 11 13 12 12 12 12 9 9 9 10 10 
Pramiracetam 8 12 12 13 14 13 13 11 11 10 9 12 
Number of vendors 43 47 50 50 52 52 52 47 47 44 44 43 
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Month 1 2 3 4 5 6 7 8 9 10 11 12 
5-HTP 7 9 9 9 10 10 10 8 8 7 6 5 
PRL-8-53 7 9 9 9 9 9 9 6 6 5 5 5 
Sunifiram 6 9 10 10 10 10 9 6 6 5 5 5 
Tianeptine 6 9 10 10 10 10 9 7 7 7 7 7 
Acetyl-L-Carnitine 5 6 7 7 6 6 6 6 6 6 6 6 
Bacopa Monniera 5 8 9 9 9 9 9 9 9 9 9 8 
Choline Bitartrate 5 8 9 9 9 9 9 8 8 8 8 7 
Citicoline 5 5 6 6 6 6 6 5 5 5 5 5 
Coluracetam 5 8 9 9 9 9 9 7 7 6 6 7 
Piracetam 5 5 6 6 6 6 6 5 6 6 6 6 
Number of vendors 43 47 50 50 52 52 52 47 47 44 44 43 
 
Although modafinil was not identified as a top ten most common nootropic, 
Adrafinil, a nootropic that metabolises as modafinil, was. Adrafinil is also a Schedule 4 
substance (Australian Government Department of Health, 2017), however it was 
available to be ordered and shipped to Australia from a variety of vendors. Adrafinil still 
being sold to Australian consumers regardless of its restrictions, may be a result of 
consumers taking the risk and ordering a less known nootropic and hoping that it will be 
processed through Australian customs. Importantly, many of the vendors indicated that 
they held no responsibility for purchases that were taken by the respective country 
customs department. The current study did not order any nootropics from vendors to 
trial if they would get past Australian customs. Adrafinil was the only nootropic in the 
top ten most common nootropics that is currently a Schedule 4 restricted substance and 
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was included in case it was available to order into Australia without being detected. Of 
note, crypto currency (e.g., Bitcoin, Skirll, light coin, Bitcoin Cash, and Ethereum), an 
online currency that offers anonymity, was accepted by 20.5% of vendors, which allows 
the purchasing of these restricted substances anonymously (Phillip, Chan, & Peiris, 
2018). The method of using anonymous currency is extensively utilised in the 
purchasing of controlled substances (e.g., ecstasy, opioids, and psychedelics), due to the 
transaction being difficult to link back to the consumer (Barratt, 2012).  
 Nootropics that through previous research have been found to have 
psychological side effects, were also discovered by the monitoring. Specifically, 
Phenibut was one of the top ten most common nootropics discovered and has been 
identified as a substance with concerning adverse side effects (McNeilage, 2018; Wong 
et al., 2015). Additionally, racetams such as Aniracetam, Oxiracetam, Phenylpiracetam, 
and Pramiracetam have been noted to result in psychopathological symptoms (e.g., 
anxiety; Nelson & Lenton, 2017). Alarmingly, some vendors provided measuring 
equipment (e.g., scales) and powder nootropics, encouraging consumers to make their 
own blends. This is of concern as nootropics research is in its infancy and there is a 
substantial gap in research focusing on the side effects of nootropics and potential 
interactions of other substances the consumer is taking. Parallels between nootropics and 
performance enhancing substances (e.g., anabolic androgenic steroids and growth 
hormones) commonly used in body building can be drawn, due to consumers often using 
substances unsupervised and without input from physicians (El-Reshaid, El-Reshaid, 
Al-Bader, Ramadan, & Madda, 2018). The body building substance literature has 
identified concerning risks such as kidney disease and heart failure (El-Reshaid et al., 
2018; White, Brennan, Ren, Shi, & Thakrar, 2018). Nootropics research requires a 
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similar focus on risk, as comparable unsupervised consumers that are encouraged to 
create homemade blends, require monitoring and accurate information regarding 
potential side effects to reduce risk (Ahmad et al., 2017; Talih & Ajaltouni, 2015; Wong 
et al., 2015).  
Although the larger nootropic market appears to be stable compared to other 
emergent substances (Bruno et al., 2013), it is important for clinicians to be aware of the 
potential side effects of nootropics (Talih & Ajaltouni, 2015). As a variety of nootropics 
are available, clinicians require an understanding of available drugs and their impacts on 
human behaviour to correctly formulate a client’s presentation. Mental health workers 
(e.g., psychologists) would benefit from more research and detailed information 
regarding the potential mental health side effects of these substances. To initiate 
increased awareness of side effects that are being experienced by consumers, Study 2 of 
this paper will explore consumer reviews for the top ten most common nootropics (as 
found in Study 1). 
As previously mentioned, a limitation of the current study is that no nootropic 
substances were ordered from vendors. Because of this, the study is limited in 
unquestionably identifying the specific nootropics that are available for the Australian 
consumer. For example, controlled substances such as modafinil and Adrafinil could be 
taken by Australian Customs and not delivered to the consumer. Additionally, consumer 
reviews reported vendors are claiming to sell certain nootropics, however after receiving 
them found they were not the nootropics they were advertised as being. Specifically, 
WEDINOS a website aimed at harm reduction by testing substances purchased online, 
found certain nootropics were not the substance the consumer had ordered (Wedinos, 25 
September, 2018). Table 5 displays examples of times consumers had ordered nootropic 
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substances (e.g., Modafinil) and when tested the substance was another (e.g., cocaine). 
Table 5 also presents examples of the times a consumer had reported negative side 
effects (e.g., hallucinations, nausea, panic attacks, agitation, and insomnia) as a result of 
taking the unanticipated substance. As the current study did not order any nootropics, it 
was not possible to verify whether the advertised nootropics were actually provided. 
Furthermore, the study was unable to note how widespread or likely it would be for a 
consumer to receive an unanticipated substance. An additional limitation is the broad 
definition of nootropic substances and the difficulty in grouping all the nootropics 
found. The current literature suggests that nootropics is a broad term that needs further 
defining, however at this stage no concrete classifications of these substances exists 
(Angeles, Ples, & Vitor, 2018). Future research should focus on defining nootropics 
further and testing nootropics for purity to better understand the market.  
Table 5 
Example of Nootropic Sample Reports that Revealed Unanticipated Substances 
(Wedinos, 25 September, 2018) 
Intended 
substance 
Year tested Actual substance Reported side effects 
Adrafinil 2015 Unable to identify Increased energy. 
Armodafinil 2017j Unable to identify Visual hallucinations, 
breathlessness, chest 
pain, nausea, panic 
attacks, and loss of 
consciousness. 
Modafinil 2014 Cocaine + Benzocaine N/A 
Modafinil 2015 Caffeine + Vitamin B3 N/A 
Modafinil 2017 Cocaine + Levamisole N/A 
Phenibut  2018 Caffeine + 
Amphetamine 
Increased energy, 
hallucinations, panic 
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attacks, nausea, 
agitation, and insomnia.  
Retrieved from http://www.wedinos.org/  
Study 2 
 Study 2 aimed to explore consumer reviews for the top ten most common 
nootropics identified in Study 1 (i.e. Adrafinil, Alpha GPC, Aniracetam, 
Centrophenoxine, L-theanine, Noopept, Oxiracetam, Phenibut, Phenylpiracetam, and 
Pramiracetam), to initiate increased awareness of the side effects being experienced by 
consumers. 
Method 
Participants 
 Participants were consumers of any of the top ten nootropic drugs identified in 
Study 1, who had reported their experiences on open Internet forums.  
Apparatus 
 Key Internet forums were examined in order to gather consumer reports of use of 
these substances (r/nootropics.com, Drugs-Forum.com, and Whirlpool.com). Due to the 
relatively scientific manner that consumers reported and described their nootropic 
experiences, these sites were identified as providing an adequate representation of the 
general consumer. Consumer reports ranged in the amount detail provided and the 
approach to individual’s reports (see Figures 7 and 8). Consent was implied due to 
consumers posting their experiences in public forums (Golder, Ahmed, Norman, & 
Booth, 2017; Roberts, 2015). All forum threads reviewed were accessible to the public, 
with consumers aware of this accessibility. 
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Figure 7. Example of a detailed consumer report. 
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Figure 8. Example of a non-detailed consumer report.  
Procedure 
 The top ten nootropic substances most commonly available to the Australian 
consumer were identified through the 12-month monitoring pilot study. The second 
study used these ten nootropics and public forums to gather consumer reports and 
experiences specifically related to these nootropics.  
 Firstly, each nootropic was examined separately via the three forums’ search tool 
to reveal available consumer reports. The aim of investigating these consumer reports 
was to identify potential risks, with a focus on adverse mental health side effects for 
each nootropic. Any consumer report that made reference to one or more of the ten 
nootropics, and one or more negative side effects was included. Consumer reports 
posted within the last 10 years were included in the study. Secondly, each nootropic was 
entered into MEDLINE (United States National Library of Medicine, 23 August, 2018), 
a database constructed by the United States National Library of Medicine, to locate any 
available case studies or literature that involved each respective nootropic. Furthermore, 
brief literature searches were conducted to construct a basic understating of each 
nootropic and its intended action. MEDLINE searches additionally provided clarity on 
the chemical structure, pharmacodynamics/pharmacology and chemical analogy (i.e. 
 
46 
 
 
similar substituted medications). Figure 9 provides visual representation of the process 
followed to create the narrative review.  
  
 
 
 
 
 
    Figure 9. Narrative review flow chart 
 
A narrative of the obtained details for each nootropic was organized and 
summarised to identify the chemical structure and potential mental health side effects. 
Overall, 73 consumer reports were reviewed (i.e. 16 for Adrafinil, eight for Alpha GPC, 
seven for Aniracetam, five for Centrophenoxine, 16 for L-theanine, three for Noopept, 
five for Oxiracetam, nine for Phenibut, four for Phenylpiracetam, and seven for 
Pramiracetam), and 85 case studies and literature reviewed.  
Nootropic online 
vendors and 
substances monitored   
Top ten most 
common nootropics 
determined 
Case studies/ 
Literature reviewed 
 Reviewed 
(n = 85) 
 
Consumer reports 
reviewed 
(n = 73) 
Narrative review of 
information gathered for 
each of the top ten 
nootropics 
Study 1 
July 2017- June 
2018 
Study 2 
June 2018- 
August 2018 
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Results 
Adrafinil  
 
a) International Union of Pure and Applied Chemistry name (IUPAC name): 
(±)-2-Benzhydrylsulfinylethanehydroxamic acid. 
b) Description: Adrafinil is a nootropic substance first discovered in 1974 by L. 
Lafon Ltd and was used for patients who were narcoleptics (Billiard & 
Broughton, in press). It was marketed in France in 1985 under the name Olmifon 
with an indication of attention and motor impairment in the elderly, and was 
withdrawn from market in 2011 as there was insufficient evidence to conclude a 
positive risk/benefit ratio from existing safety and efficacy data (French National 
Agency for Medicines and Health Products Safety, 25 July, 2018). Once 
Adrafinil is consumed, it metabolises and becomes modafinil. Adrafinil has 
similar reported benefits (e.g., wakefulness and focus) as modafinil, however has 
been noted by consumers to be less effective. Animal studies have revealed that 
Adrafinil increases EEG (electroencephalograph) activity in the prefrontal cortex 
and has potential as a novel behavioural stimulant (i.e. increased locomotion and 
alertness), with the underlying mechanism of action still being unclear (Siwak, 
Callahan, & Milgram 2000; Siwak, Gruet, Woehrlé, Muggenburg, Murphey, & 
Milgram, 2000; Siwak, Tapp, & Milgram 2003). Conversely, Siwak et al. (2003) 
reported a significant decrease in working memory of beagles when given 
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Adrafinil, with these authors suggesting that this effect may have arisen from an 
observed increase in noradrenergic transmission in the prefrontal cortex.  
c) Chemical analogy: As previously stated, Adrafinil metabolises to modafinil, a 
well-known prescription nootropic. Similar to Adrafinil, the exact mechanism of 
action of modafinil is unknown (Billiard & Broughton, in press). Clinical trials 
have indicated efficacy of modafinil in the treatment of narcolepsy and excessive 
sleepiness due to obstructive sleep apnoea and shift work. The Consumer 
Medicine Information (CMI; Consumer Medicine Information, 2017) product 
information sheet for modafinil includes a number of adverse side effects 
including increased aggressive behaviour, increased suicidal ideation, worsening 
of psychotic/manic symptoms, increased depressive symptoms, and increased 
anxiety.  
d) Case studies: Thobois, Xie, Mollion, Benatru, and Broussolle (2004) examined 
the case of a 75-year-old male who developed repetitive involuntary facial 
movements (i.e. orofacial dyskinesia) as a result of Adrafinil, prescribed for 
excessive daytime sleepiness. These symptoms persisted for four months after 
the Adrafinil was ceased. Thobois et al. (2004) noted that this was the first 
reported case of Adrafinil induced orofacial abnormal movements, with the 
reason for this interaction remaining unclear.  
e) Reported psychological side effects: There were 16 consumer experience 
reports identified for Adrafinil. Four consumers identified in the current study, 
reported feelings of increased anxiety. Additionally, anti-social traits were 
indicated by a consumer who noted feeling “cold blooded” and “cold hearted” 
 
49 
 
 
(Reddit Consumer). Another consumer indicated feeling hyperactive and 
obsessive at times.  
f) Other reported side effects: Consumers in the current study reported low 
energy, sleeping difficulties, tiredness, physical discomfort, skin irritation, 
dizziness, nightmares, and strained vision.  
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Alpha GPC  
 
a) IUPAC name: [(2R)-2,3-Dihydroxypropyl] 2-trimethylazaniumylethyl 
phosphate. 
b) Description: L-Alpha glycerylphosphorylcholine (Alpha GPC) is a nootropic 
that aims to enhance memory and learning by increasing the release of 
acetylcholine in the brain (Parker, Byars, Purpura, & Jäger, 2015). Alpha GPC 
has shown potential in reducing the symptoms of dementia (e.g., memory loss 
and alertness; Muratorio et al., 1992; Perri, Coppola, Ambrosio, Grasso, Puca, & 
Rizzo, 1991; Scapicchio, 2013). Cruse (2018) examined the cognitive impacts in 
a small sample (n = 27) of young adults, with findings suggesting that 
individuals who were given Alpha GPC performed significantly better in terms 
of reaction time on computer-based assessment tools. Cruse (2018) noted an 
absence of literature regarding the cognitive benefits of Alpha GPC. In addition 
to the cognitive benefits, Alpha GPC has also been assessed for its possible 
physical benefits (Marcus, Soileau, Judge, & Bellar, 2017). The US Food and 
Drug Administration have recognised that doses to a maximum of 196.2 mg/day 
meets the ‘Generally Recognised as Safe’ criteria (Heimbach, 2012).  
c) Chemical analogy: Choline or acetylcholine (Parnetti, Mignini, Tomassoni, 
Traini & Amenta, 2007). Alpha GPC is a precursor to choline and acetylcholine 
(on ingestion it is converted to phosphorylcholine and then to choline which is 
then available for biological synthesis of acetylcholine; Parnetti et al., 2007).  
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d) Case studies: To the authors knowledge no case studies have been published on 
Alpha GPC.  
e) Reported psychological side effects: There were eight consumer experience 
reports identified for Alpha GPC.  Consumers reported anxiety after using Alpha 
GPC. One consumer stated “I couldn't believe it was anxiety at first either but it 
is. It was hard for me to believe it was anxiety at first too because I've always 
associated anxiety with how I feel in my mind, but for some reason in these 
situations it's just that we feel the physical effects of anxiety more than usual i.e. 
shortness of breath” (Reddit Consumer). In addition to anxiety, consumers 
reported low mood (e.g., “I got SO depressed after taking it. Darkest I've ever 
been”; Reddit Consumer). Other consumers reported increased irritability, but 
not low mood (e.g., “It can make me irritable, but not depressed usually”; Reddit 
Consumer).  
f) Other reported side effects: Consumers reported weight gain, low blood 
pressure, poor sleep, and mild headaches. Given that Alpha GPC increases 
choline levels in the central nervous system, this will interact with other 
acetylcholine enhancing medications such as those used in dementia; and will 
interact with acetylcholine inhibitors such as anticholinergics.  
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Aniracetam  
 
a) IUPAC name: 1-[(4-Methoxybenzoyl)]-2-pyrrolidinone. 
b) Description: Aniracetam is also known as N-anisoyl-2-pyrrolidinone and is a 
positive allosteric modulator at AMPA (alpha-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid) glutamate receptors (Reynolds et al., 2017; Lee & 
Benfield, 1994). Given that glutamate is a general excitatory neurotransmitter, 
aniracetam may also increase cholinergic transmission (Lee & Benfield, 1994; 
Schindler, Rush, & Fielding, 1984). This nootropic has shown potential for 
treating individuals with brain injuries, epilepsy, dementia (e.g. Alzheimer’s), 
and neurodevelopmental disorders (e.g., Autism, ADHD, and Schizophrenia; 
Reynolds et al., 2017). It is sold as a pharmaceutical in Italy (Ampamet), China 
(Aniracetam-Sanhome, Bi Si Ling, Bo Bang Lin, San Le Xi, Shuntan and Yi 
Ling Shu), Greece (Memodrin, Referan) and by Pfizer in Argentina (Pergamid). 
Research investigating potential side effects of racetams notes no adverse side 
effects in animal studies (Gouliaev & Senning, 1994; Reynolds et al., 2017).   
c) Chemical analogy: The opposite of benzodiazepines. Benzodiazepines are 
positive allosteric modulators of the general inhibitory neurotransmitter, GABA, 
and work by enhancing the natural effect of GABA at GABA receptor sites. 
Aniracetam is a positive allosteric modulator of the general excitatory 
neurotransmitter, glutamate, enhancing its effect at AMPA receptor sites.  
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d) Case studies: Nagasaka et al. (1997) reviewed two case studies of older adults 
(i.e. 72-year-old male and 68-year-old female) both with a diagnosis of 
progressive supranuclear palsy who were treated with Aniracetam to improve 
both cognitive (i.e. memory) and physical (i.e. walking) symptoms. There were 
no reported adverse side effects in these case studies (Nagasaka et al., 1997). 
Similarly, a case study of three females who had dementia and were using 
Aniracetam to treat symptoms reported no adverse side effects (Mizuki et al, 
1984).  
e) Reported psychological side effects: There were seven consumer experience 
reports identified for Aniracetam. Reports of psychological side effects were 
limited for Aniracetam. One consumer reported that the nootropic caused them 
to have a change in mood that was described as more “energising rather than 
calming” (Reddit Consumer), however did not explicitly state feelings of 
anxiety. Another reported consuming Aniracetam to assist with their symptoms 
of ADHD and experienced symptoms of mild depression (e.g., “I've been a little 
depressed”; Reddit Consumer). Cognitive effects such as brain fog, confusion, 
and incoherence were also noted.  
f) Other reported side effects: Consumers reported sleeping deficits, build-up of 
tolerance, headaches, and fluctuating libido. Given that Aniracetam is a positive 
allosteric modulator of glutamate, it could be expected that this would be 
counter-indicated for individuals susceptible to seizures and for other conditions 
with dysregulation of glutamate, including schizophrenia.  
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Centrophenoxine  
 
a) IUPAC name: 2-Dimethylaminoethyl (4-chlorophenoxy) acetate. 
b) Description: Centrophenoxine, also known as meclofenoxate, is made from the 
amino acids dimethylamine-ethanol (DMAE) and p-chlorophenoxyacetic acid 
(Nandy & Bourne, 1966). It is sold as a pharmaceutical in Japan (Lucidril, 
Meclosert), Taiwan (Lisu) and Egypt (Lucudrul, Luciforte). In these cases, the 
drug is marketed as a treatment for cognitive impairment associated with ageing 
or strokes (PubChem, 15 August, 2018). It has variously been considered to 
assist in slowing the process of neuronal sentence (i.e. the process of gradual 
deterioration because of ageing; Riga & Riga, 1974). Nagy and Semsei (1983) 
noted that Centrophenoxine has shown to increase actions that facilitate slower 
degradation of neurons (i.e. glucose and oxygen absorption).  
c) Chemical analogy: Choline or acetylcholine. Meclofenoxate has been studied as 
a cholinergic enhancer and increases production of choline which is also 
available for conversion into acetylcholine (National Center For Advancing 
Translational Sciences, 15 August, 2018).  
d) Case studies: To the authors knowledge no case studies have been published on 
Centrophenoxine. In published trials of the drug, no adverse effects were 
reported among older adults (Oliver & Restell, 1967). In a study exploring the 
effectiveness of Meclofenoxate in the treatment of tardive dyskinesia, 
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participants reported marked increases in parkinsonism movements (Izumi et al., 
1986).  
e) Reported psychological side effects: There were five consumer experience 
reports identified for Centrophenoxine. Of the limited consumer reports available 
for Centrophenoxine, few made mention of any mental health side effects. One 
consumer reported that there was a notable increase in irritability (e.g., “I 
became easy irritated by small things”; Reddit Consumer), while another 
consumer indicated feeling depressed (e.g., “Centrophenoxine make me 
depressed” Drug-forum Consumer).  
f) Other reported side effects: Consumers reported heart burn, sleeping 
difficulties, and withdrawal (e.g., “I get really, really tired when it wears off” 
Reddit Consumer). Given that Centrophenoxine increases choline levels in the 
central nervous system, this will interact with other acetylcholine enhancing 
medications such as those used in dementia; and will interact with acetylcholine 
inhibitors such as anticholinergics. 
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L-theanine  
 
a) IUPAC name: (2S)-2-Ammonio-5-(ethylamino)-5-oxopentanoate or N-Ethyl-L-
glutamine. 
b) Description: Theanine is an amino acid that has been identified in green tea 
leaves (Kahathuduwa et al., 2018). There are two chiral forms of theanine, but 
the majority of research has been conducted on the levo enantiomer (L-theanine; 
National Centre for Advancing translational Sciences, 12 August, 2018). Interest 
in this nootropic has arisen due to its potential to increase cognitive performance 
(e.g., alertness and attention; Kahathuduwa et al., 2018). Additionally, there have 
been some indications of its potential to be a relaxing agent (Kimura, Ozeki, 
Juneja, & Ohira, 2007; Ogawa, Ota, Ogura, Kato, & Kunugi, 2017). L-theanine’s 
mechanism of action is by blocking certain acids (i.e. L-glutamic acid) to 
receptors (i.e. glutamate) (Kimura Et al., 2007).  
c) Chemical analogy: Anxiolytic by reducing excitatory neurotransmission. 
Theanine is structurally similar to glutamate and as such demonstrates binding at 
glutamate sites. It acts as an antagonist at AMPA and kainite glutamate receptors 
and as a weak agonist at the glutaminergic NMDA receptors (Nasiroleslami, & 
Mohitmafi, 2015; Nathan, Gary & Oliver, 2006). In animal studies this also 
appears to produce some enhancement in serotonin, dopamine and GABA 
activity (Nathan et al, 2006).  
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d) Case studies: To the authors knowledge no case studies have been published on 
L-theanine. A review of L-theanine by the Japan Food Additives Association 
indicated no adverse side effects related to L-theanine (Juneja, Chu, Okubo, 
Nagato, & Yokogoshi, 1999). The US Food and Drug Administration has 
granted L-theanine ‘Generally Recognised as Safe’ status. The European Food 
Safety Authority (2011) have published a scientific opinion statement that there 
is insufficient evidence for companies to claim improvement in cognition, 
reductions in stress, or improvement in sleep associated with L-theanine 
(PubChem, 12 August, 2018).  
e) Reported psychological effect: There were 16 consumer experience reports 
identified for L-theanine. Consumers found it difficult to relax and experienced 
greater anxiety (e.g., “anxiety spikes which then causes me to lose sleep”; Reddit 
Consumer). Additionally, consumers reported decreased mood (e.g., “I've 
noticed every time I take it I get depressed all day”; Reddit Consumer), and 
irritability (e.g., “It makes me grumpy”; Reddit Consumer). Consumers also 
reported feeling disorientated and having lower concentration when taking L-
theanine. 
f) Other reported side effects: Consumers reported decreased energy, difficulty 
regulating bowel movements (e.g., “I’m experiencing bad side effects diarrhea 
and constipation”; Reddit Consumer), sleeping deficits, increased sweating, 
dizziness, and decreased libido (e.g., “It made my penis stop working after two 
weeks of regular use”; Reddit Consumer). Additionally, consumers reported 
addictive traits (e.g., “I realise this drug can get very addicting” Drugs-forum 
Consumer).   
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Noopept  
 
a) IUPAC name: N-phenylacetyl-l-prolyglycine ethyl ester  
b) Description: Noopept is the trade name for omberacetam, patented in both the 
US and Russia. It aims to stimulate broad areas of the brain to improve memory 
and learning (Kolbaev, Aleksandrova, Sharonova, & Skrebitsky, 2018). These 
substances have been used to potentially help individuals with dementia (e.g., 
Alzheimer’s and Parkinson’s) and mild cognitive impairments following 
physical trauma (e.g., traumatic brain lesions; Kolbaev et al., 2018). Animal 
studies have suggested that noopept may protect against neuron damage through 
inhibition of excessive calcium and from oxidative damage, and also block key 
components of cellular apototosis (Ostrovskaya, et al, 2014). Rodent models 
have also suggested increases in the neuroprotective Brain Derived Neurotrophic 
Factor (BDNF) (Ostrovskaya et al, 2008).  
c) Chemical analogy: While the mechanism of action is as yet unconfirmed, 
possibly the best available analogy would be of enhanced recovery from cellular 
injury from inflammatory or free radical processes (National Centre for 
Advancing Translational Sciences,15 August, 2018; PubChem, 15 August, 
2018).  
d) Case studies: To the author’s knowledge no case studies have been published on 
Noopept.  
 
59 
 
 
e) Reported psychological effect: There were three consumer experience reports 
identified for Noopept. Two consumers reported feeling anxious (e.g., “It made 
me feel pretty tweaky and anxious”; Reddit Consumer). There were also reports 
of cognitive difficulty (e.g., “My head began to just crash. I felt like a hungover 
drunk with maybe a little high mixed in, but it was just awful”; Drugs-forum 
Consumer). 
f) Other reported side effect: Consumers reported physical pain (e.g., 
“muscle/joint stiffness”; Reddit Consumer) and decreased energy (e.g., “I was 
getting more exhausted/drained towards the end of the day”; Reddit Consumer). 
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Oxiracetam  
 
a) IUPAC name: (RS)-2-(4-hydroxy-2-oxopyrrolidin-1-yl) acetamide. 
b) Description: Oxiracetam is a racetam described as a new nootropic that aims to 
regulate rates of glutamate and cholinergic transmission and additionally 
enhance cerebral glucose levels particularly in the hippocampus (Hu, Shi, Xiong, 
Li, Fang, & Feng 2017; Marchi, Besana, & Raiteri, 1990). Oxiracetam has been 
used to help with memory and learning difficulties, particularly for individuals 
with vascular dementia (Hu et al., 2017).  
c) Chemical analogy: As Oxiracetam is a racetam its chemical analogy is the same 
as Aniracetam and has been related in structure to nootropics such as 
Aniracetam, Phenylpiracetam, and Pramiracetam. As such it is the opposite of 
benzodiazepines. Benzodiazepines are positive allosteric modulators of the 
general inhibitory neurotransmitter, GABA, and work by enhancing the natural 
effect of GABA at GABA receptor sites. Oxiracetam is a positive allosteric 
modulator of the general excitatory neurotransmitter, glutamate, enhancing its 
effect at AMPA receptor sites.  
d) Case studies: Gou, Peng, and Ynag (2018) present a case study of an 84-year-
old who consumed Oxiracetam with the packaging still intact. The adverse side 
effect (i.e. damage to the small intestine) experienced was attributed to the 
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packing being intact rather than Oxiracetam (Gou et al., 2018). No other case 
studies were revealed.   
e) Reported psychological effect: There were five consumer experience reports 
identified for Oxiracetam. Consumers indicated a decrease in cognitive ability 
(e.g., brain fog, short term memory deficits, and forgetfulness). One consumer 
reported a decline in cognitive ability and an increase in anxiety symptoms (e.g., 
“This shit scared the fuck out of me; brain fog, anxiety, short-term memory 
problems etc plagued me for three days straight and I thought I lost any form of 
higher order thinking”; Reddit Consumer). Another consumer indicated a mild 
change in mood (e.g., “slightly more irritable; Drugs-forum Consumer).   
f) Other reported effects: Other than the psychological side effects, consumers 
reported limited effects for Oxiracetam. One consumer indicated low energy 
(e.g., “I was quite jittery and very forgetful, couldn't get myself to do anything”; 
Reddit Consumer). 
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Phenibut  
 
a) IUPAC name: 4-Amino-3-phenylbutanoic acid. 
b) Description: 4-amino-3-phenylbutyric acid (Phenibut) is a nootropic that is a 
derivative of gamma-aminobutyric acid (GABA; Joshi, Friend, Jimenez, & 
Steiger, 2017). It is licenced as a pharmaceutical in some countries (Drugs.com, 
20 august, 2018): in China (An Luo, Change Rui, Hui You, Kai Luo, Li Sheng 
Bei Fen, Lu Bi An, Sheng Mai Fu, Ti Ta Ding, Tu Ti, Tuo Tai, Wei Ding, Xin 
Nuo Shu, Yi An Fen, Yi Hui Luo, Zhu Zhong Xin); Thailand (Bainto); 
Argentina (Butineuron); Egypt (Gaba); Japan (Gammalon); Brazil (Gammar), 
and Russia (Phenibut). It has been used to help individuals with alcohol 
withdrawal, sleep disorders (e.g., insomnia), and anxiety (Joshi et al., 2017).  
c) Chemical analogy: Baclofen. Because Phenibut is structurally very similar to 
GABA it can act as a GABA analogue, binding at similar locations, particularly 
the GABAb receptor sites. Baclofen, a medication used in muscular disorders 
and increasingly in alcohol dependence, works as an agonist at the GABAb sites 
as well. As such, this drug acts as a CNS depressant, with motor relaxing, sleep 
enhancing and anxiolytic effects.  
d) Case studies: Sankary, Canino, and Jackson (2017) described a case of a 25-
year-old male who presented to the emergency room after a concerned friend 
noted abnormal behaviours (i.e. acting erratically, confusion, and what appeared 
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to be seizures). The man had ingested Phenibut he purchased online shortly 
before these symptoms appeared. Sankary et al. (2017) noted that Phenibut was 
likely the cause of symptoms, however this was unable to be confirmed due to 
adequate blood tests not being readily available to emergency rooms. Another 
case involved a 20-year-old female who presented to the emergency room with 
increased levels of confusion and delirium (Downes et al., 2015). It was 
established that she had consumed Phenibut that she had purchased online 
(Downes et al., 2015). Brunner, Healtheast, and Paul (2017) noted a case where 
an individual was admitted to the emergency room due to withdrawal symptoms 
that were later determined to be a result of Phenibut dependence. Although 
limited information was given, it was reported by Brunner et al. (2017) that this 
case is an example of why Phenibut should not be readily available and 
regulation guidelines should be explored more thoroughly, so recommendations 
can be made in regard to dependence. A 25-year-old man who was found 
unconscious on the floor of his apartment by a friend had reportedly been using 
Phenibut purchased on the internet for four days (O’Connell, Scheir, Hwang, & 
Cantrell, 2014). Samokhvalov, Paton-Gay, and Balchand (2013) reported a case 
of a 35-year-old male IT specialist who had purchased Phenibut to self-medicate 
his anxiety symptoms. The man presented with concerns regarding not being 
able to stop taking the Phenibut due to withdrawal symptoms (i.e. increased 
anxiety, low mood, and irritability) and required medical advice (Samokhvalov 
et al., 2013). The man was prescribed Baclofen to taper off the Phenibut use 
(Samokhvalov et al., 2013). It was reported that after nine weeks the man was 
able to stop using Phenibut without experiencing further withdrawal symptoms. 
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As previously mentioned in the introduction of this paper, Wong et al. (2015) 
described a 43-year-old male who had consumed Phenibut, who presented to the 
emergency room with increased agitation and involuntary muscle contractions. 
Due to the severity of his symptoms he had to be stabilised in the intensive care 
unit. All case studies involving Phenibut indicated a gap in identifying Phenibut 
as the cause of symptoms due to insufficient screening tools and clinical research 
explaining the reason behind the experienced symptoms (Downes et al., 2015; 
O’connell, et al., 2014; Samokhvalov et al., 2013; Sankary et al., 2017; Wong et 
al., 2015).  In addition to formal case study’s a media article mentioned in the 
introduction of this paper reported a group of Australian school-age children 
who were hospitalised as a result of dizziness and nausea related to consuming 
Phenibut (McNeilage, 2018). 
e) Reported psychological effect: There were limited consumer reports indicating 
psychological side effects. Two consumers indicated an increase in anxiety, with 
one also indicating additional changes in mood (e.g., “The anxiety occurs mostly 
from the overwhelming sensory stimuli… rebound anxiety and irritability”; 
Whirlpool Consumer).  
f) Other reported effects: Consumers reported impaired vision, nausea, and 
increased hunger. Consumers also indicated addictive properties leading to 
experiences such as withdrawal (e.g., “Nasty withdrawal effects. Therefore, I am 
very careful about how often I use it and also my dosage when I use it”; Drugs-
forum Consumer), and identified it as dangerous (e.g., “It’s very similar in effect 
to alcohol and xanax. I consider it more of a drug than a noot”; Reddit 
Consumer).  
 
65 
 
 
Phenylpiracetam  
 
a) IUPAC name: (R,S)-2-(2-oxo-4-phenylpyrrolidin-1-yl)acetamide. 
b) Description: Phenylpiracetam (also sold as Fonturacetam, Carphedon, Karfedon, 
Carphedone, and 4-phenylpiractam), is structurally similar to other drugs in the 
racetam family. Phenylpiracetam is another racetam that aims to increase 
cognitive ability, originally used to increase cognitive capacity of Soviet space 
crews (Veinberg et al., 2015). Phenylpiracetam’s pharmacological nature is 
described as similar to other racetams (i.e. glutamate cholinergic transmission; 
Lee & Benfield, 1994), however additionally has an anticonvulsant action 
(Bobkov, Morozov, Glozman, Nerobkova, & Zhmurenko, 1983). Like other 
racetams, this nootropic has been used to assist individuals with traumatic brain 
injury, stroke, and dementia (Veinberg et al., 2015).  
c) Chemical analogy: As Phenylpiracetam is a racetam, its chemical analogy is the 
same as Aniracetam and has been related in structure to nootropics such as 
Aniracetam, Oxiracetam, and Pramiracetam. As such it is the opposite of 
benzodiazepines. Benzodiazepines are positive allosteric modulators of the 
general inhibitory neurotransmitter, GABA, and work by enhancing the natural 
effect of GABA at GABA receptor sites. Oxiracetam is a positive allosteric 
modulator of the general excitatory neurotransmitter, glutamate, enhancing its 
effect at AMPA receptor sites.  
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d) Case studies: To the authors knowledge no case studies have been published on 
Phenylpiracetam.  
e) Reported psychological effects: There were four consumer experience reports 
identified for Phenylpiracetam. Limited psychological effects were noted by 
consumers. One review indicated anxiety as a result of Phenylpiracetam, while 
another indicated cognitive decline (e.g., “had brain fog for the following few 
hours”; Reddit Consumer).  
f) Other reported side effects: Consumers reported sleep deficits, headaches, and 
physical discomfort (e.g., “I developed a headache, which is hard to say how 
much was the drug I didn't die obviously or need to go to a hospital, and by the 
next day the negative effects had worn off”; Reddit Consumer).  
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Pramiracetam  
 
a) IUPAC name: N-[2-(Diisopropylamino) ethyl]-2-(2-oxopyrrolidin-1-yl) 
acetamide. 
b) Description: Pramiracetam is another racetam that has been noted to increase 
learning and memory, and additionally protect neurons (Angeles, et al.,2018). It 
is also known as amacetam, pramiracetamum, neupramir, and ectapram 
(PubChem, 21 August, 2018). An investigation into the chemical nature of 
Pramiracetam revealed similar regulation of glutamate and cholinergic 
transmission as other racetams, with specific release in the corpus stratum and 
cerebral cortex (Pugsley, Shih, Coughenour, & Stewart, 1983). This nootropic is 
also identified as potentially useful for individuals with dementia (e.g., 
Alzheimer’s and frontotemporal dementia), epilepsy, partial seizures, and 
anxiety (Angeles et al., 2018). 
c) Chemical analogy: As Pramiracetam is a racetam its chemical analogy is the 
same as Aniracetam and has been related in structure to nootropics such as 
Aniracetam, Oxiracetam, and Phenylpiracetam. As such it is the opposite of 
benzodiazepines. Benzodiazepines are positive allosteric modulators of the 
general inhibitory neurotransmitter, GABA, and work by enhancing the natural 
effect of GABA at GABA receptor sites. Oxiracetam is a positive allosteric 
modulator of the general excitatory neurotransmitter, glutamate, enhancing its 
effect at AMPA receptor sites.  
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d) Case studies: To the author’s knowledge no case studies have been published on 
Pramiracetam. 
e) Reported psychological effects: There were seven consumer experience reports 
identified for Pramiracetam. Consumer reports identifying side effects were 
limited for Pramiracetam, however there was one report of mood changes (e.g., 
“Makes me really depressed and lethargic after chronic use”; Reddit 
Consumer). Interestingly, one consumer reported difficulty controlling affect 
(e.g., “I was so into my own thought that I have been making facial expressions 
… I tried to stop but I just couldn't help but react, I was mostly just smiling and 
nodding to a few good ideas I had”; Reddit Consumer).  
f) Other reported effects: Consumers reported physical pain (e.g., 
“Pramiracetam can cause burns in the mouth”; Reddit Consumer) and 
headaches. One consumer identified addictive properties in relation to quickly 
building tolerance.  
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Preliminary Discussion 
The 12-month monitoring revealed a variety of nootropics available to the 
Australian consumer. Of these identified nootropics, the top ten most common 
substances were examined in more detail by reviewing consumer reports on online 
forums. Study 2 gathered information to identify the chemical structure, a brief 
description, chemical analogy, published case studies, and reported side effects of each 
nootropic in the top ten most common nootropics identified. Through this exploration of 
consumer reports, the current study found instances where individuals experienced 
adverse mental health side effects as a result of using these nootropics. The current 
study did not obtain information regarding the prevalence of each nootropics use, and 
future research is needed to substantiate these consumer reported experiences.  
 Previous findings have indicated both mental health and physical side effects for 
various nootropics (Nelson & Lenton, 2017; Ragan et al., 2012; Talih & Ajaltouni 2015; 
Wong et al., 2015). The narrative review of nootropic consumer reports further supports 
these findings. Regarding psychological side effects, consumers reported low mood 
(e.g., depression), an increase in anxiety, irritability, and cognitive decline (e.g., brain 
fog). However, whether these side effects were due to the respective nootropic 
consumption is still unclear. Consumers also reported a range of other side effects such 
as physical pain (e.g., headaches), sleep disturbances, and addictive experiences (e.g., 
withdrawal and tolerance symptoms). Often consumers would indicate that when 
negative side effects arose, they would decrease the dose of nootropic, often informed 
by other consumer reports, with varying levels of success. Similarly, consumers often 
reported increasing the dose of nootropic if the desired cognitive benefit was not 
achieved. This was concerning and commonplace, with many consumers indicating this 
pattern of nootropic consumption. The findings from the consumer reports further 
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support the hypothesis that nootropics have harmful side effects and require structured 
research to more accurately inform consumers of their risk and benefit.   
A review of case studies revealed concerning cases of nootropic risk. 
Particularly, case studies that involved Phenibut revealed the potential dangers of taking 
substances purchased online. These cases highlighted the need for nootropics to undergo 
the four-phase clinical trial process to ensure safety for consumers. In addition to further 
testing, the nootropics available to consumers need to be regulated in regard to their 
manufacturing to ensure safety. The Good Manufacturing Practice (GMP; Australian 
Government Department of Health, 2017) outlines policies and procedures to ensure 
products contain the right amount of advertised substances. Nootropics that contain 
variable rates of substance due to poor manufacturing would present greater risk to the 
consumer. The analogues approach only provided a general guide to substances that are 
similar in their mechanism of action. However, it revealed some similar medications 
(e.g. Modafinil and Baclofen) have well documented adverse outcomes for consumers. 
In the case of Phenibut, Baclofen were found to be a potential analogue as a result of 
Phenibut’s interaction with GABA. Although the effect appears on a smaller scale, 
taking a large amount of Phenibut may have similar outcomes as Baclofen and therefore 
poses similar risk. These risks need to be explored by future research in order to ensure 
the safety of consumers. The common racetam drugs identified (e.g., Aniracetam, 
Oxiracetam, and Phenylpiracetam), appeared to have less reported negative side effects 
through both chemical analogy and case studies. It is possible that these nootropics pose 
less risk to consumers, however further research is required to identify possible side 
effects and safe dosages for these nootropics to be considered safe and therefore sellable 
to an online marketplace.  
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 Several limitations of the current study are related to the method of gathering 
information solely from consumer reports. As displayed in the method, consumer 
reports ranged in the amount of detail provided and the approach to individual’s reports 
(see Figures 7 and 8). In some cases, the consumer would detail the amount of the 
nootropic they were taking, whereas other consumers did not report this information. 
This limits the study’s ability to investigate at what amount a certain nootropic had 
adverse side effects. Similarly, difficulty was found when consumers did not report 
individual information regarding weight, height, and age, which may have impacted the 
function of these nootropics. Another key challenge in generalising these results is that 
often consumers did not indicate whether and what other substances there were using, 
that may have impacted or compounded the reported side effects. The current study 
recognises these limitations and does not claim the reported side effects experienced 
were a result of the nootropic used. This research aims to provide this information as a 
foundation base, where consumer reports of side effects informs more structured future 
research.  
 Study 2 has provided a snapshot of psychological and other side effects of the 
top ten most common nootropics available to the Australian consumer, as experienced 
and reported by consumers. The current study adds to the growing body of literature 
regarding nootropics and provides a foundation for future research. Due to the variety of 
available nootropics and their increasing popularity, particularly for university students, 
clinicians should be aware of the potential side effects consumers may experience when 
using common nootropics. Additionally, as the literature grows in this area, it will be 
useful to have an understanding of potential for interactions with other medications and 
recreational substances.  
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Discussion 
The current two-part study aimed to firstly monitor the nootropic online market 
over a 12-month period, identifying vendors and nootropics available to the Australian 
consumer. From the monitoring conducted, Adrafinil, Alpha GPC, Aniracetam, 
Noopept, Oxiracetam, Phenibut, Centrophenoxine, L-theanine, Phenylpiracetam and 
Paramiracetam were identified as the ten most common nootropics. The monitoring had 
several limitations associated with ambiguity of whether restricted substances were still 
obtainable to Australian consumers. Furthermore, substances were not tested to confirm 
if they were in fact the nootropic advertised. Despite these limitations, the monitoring 
successfully observed nootropics available to the Australian consumer over a 12-month 
period. Overall, the results indicated a stable market for nootropics.  
Focusing on the top ten nootropics, the second study provided a review of 
consumers experiences posted on public forums. Consistent with previous research 
(Ragan et al., 2012; Talih & Ajaltouni 2015; Wong et al., 2015; Nelson & Lenton, 
2017), several psychological and other side effects were reported by consumers, 
highlighting the potential adverse side effects of nootropics. As previously mentioned, 
the second study was limited in that the information reviewed was in the form of 
consumer reports and therefore identifying a direct link with side effects and nootropic 
use was not possible. With these limitations in mind, the current study aimed to provide 
an overview of side effects experienced and reported by consumers, to stimulate future 
research with a focus on enhanced scientific methods.  
In its entirety, the current study holds several clinical implications that will be 
useful for consumers and mental health clinicians treating nootropic consumers. An 
understanding of available common nootropics and their associated side effects as 
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experienced by consumers will add to treatment considerations. For example if a client 
is consuming a nootropic purchased for perceived cognitive benefits they may have 
exacerbated mental health symptoms (e.g. anxiety and depression) that need to be 
considered for diagnosis and treatment. With the growing nootropic market and 
prevalence of their use, it is important to understand these new substances and how they 
may affect individuals (e.g. possible physical and mental health side effects, interactions 
with other substances, and other possible risks). 
The consumer reports indicated that individuals using nootropics are 
experiencing adverse psychological side effects and therefore, may seek help from a 
clinician. Clinicians will need to understand the potential side effects of these 
nootropics, so they can effectively educate clients of the potential harms to their 
physical and mental health. Although this study focuses on nootropics available to the 
Australian consumer, these substances are also available internationally and therefore 
this information may be of use to clinicians outside of Australia. The study highlights 
the importance for clinicians to maintain up to date knowledge on non-prescription 
medication that may have an adverse effect for their clients who consume them. The 
current study has presented consumer reports and therefore, the information should be 
examined with caution and be used to inform possible areas for future research.  
Future research is needed to further explore the side effects of nootropics, as 
knowledge of potential harms is crucial for both consumers and clinicians. The current 
study did not focus on the reported positive experiences of nootropic consumers. Future 
research exploring the effects of nootropics on improving cognitive performance in 
human samples would allow consumers to have an informed understanding of the 
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efficacy of nootropic use. In addition to informing clinicians of negative effects, 
identifying harms can be used to inform policy change regarding nootropics.  
This study shows that a substantially sized, online nootropic market is available 
to the Australian consumer. Cumulatively, vendors have a variety of nootropic 
substances available for purchase and delivery to Australia. Although some nootropics 
are restricted in Australia, they are still available for purchase online, and if passed 
through Australian Customs, are accessible to consumers. A growing body of consumer 
reports for common nootropics exists, many of which indicate adverse side effects to be 
cautious of. Both clinicians and policy makers should be aware of nootropics and aim to 
appropriately inform and caution consumers of their potential harmful effects.   
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Appendix A 
Nootropic Internet Forums Examined for Search Terms 
1. www.reddit.com/r/Nootropics 
2. www.4chandata.org/fit/NOOTROPICS-THREAD 
3. www.drugs-forum.com/forums/nootropics 
4. www.nootropicsexpert.com/community-forum 
5. www.whirlpool.net.au 
6. www.longecity.org/forum 
7. www.neuronootropic.com 
8. www.anabolicminds.com 
9. https://piracetam.net/forum/ 
10. www.excelmale.com/ 
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Appendix B 
Search Terms Tested 
1. Smart Drugs 
2. Nootropics Australia 
3. modafinil 
4. Nootropic 
5. Noot 
6. Alpha Brain 
7. Cognitive Enhancer 
8. Racetams 
9. L-theanine 
10. Theanine 
11. Creatine 
12. Bacopa Monnieri 
13. Ashwaganda 
14. Chaga 
15. NSI-189 
16. NDRI 
17. Bacopa 
18. Noopept 
19. Semax 
20. Vyvanse 
21. Adderall 
22. cognitive drugs 
23. Alpha Brain 
24. Onit 
25. Ginkgo Biloba 
26. Rhodiola Rosea 
27. Siberian Ginseng 
 
 
 
 
 
 
 
 
